Joel Rämö will defend his doctoral dissertation “Genomic, metabolic and clinical profiling of dyslipidemias in families” on November 6. Cardiovascular diseases account for 30-40% of deaths in Western ...

AI-Driven Identification and Outreach for Familial Hypercholesterolemia: Early Results from the FIND FH Initiative at a Single Academic Center Saturday, Nov. 8 at 1:45-2:55 pm, Population Science Zone ...

DL defines abnormalities in the lipid profile caused by both genetic and acquired metabolic disorders. Most of the genetic lipid disorders are dominantly inherited and include familial ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — In this video from the National Lipid Association Scientific Sessions, James Underberg, MD, MS, ...

Please provide your email address to receive an email when new articles are posted on . Among people who ordered a genetic test for dyslipidemia, younger people were more likely to have a positive ...

In spite of growing interest in genetic testing for patients with dyslipidemia, there have been few clear clinical indications and no practice guidelines. That just changed. A new scientific statement ...

More than half of the drugs given to children and youth in hospital are used off label. Although therapy given to adults is usually guided by evidence, the evidence for the use of these drugs in ...

PALO ALTO, Calif.--(BUSINESS WIRE)--OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of assets relating ...